The success of anti-PD-1 with chemotherapy for esophageal squamous cell carcinoma

Song, 2023, First-line serplulimab or placebo plus chemotherapy in PD-L1-positive esophageal squamous cell carcinoma: a randomized, double-blind phase 3 trial, Nat. Med., 29, 473, 10.1038/s41591-022-02179-2 Janmaat, 2017, Palliative chemotherapy and targeted therapies for esophageal and gastroesophageal junction cancer, Cochrane Database Syst. Rev., 2017 Sun, 2021, Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study, Lancet, 398, 759, 10.1016/S0140-6736(21)01234-4 Doki, 2022, Nivolumab combination therapy in advanced esophageal squamous-cell carcinoma, N. Engl. J. Med., 386, 449, 10.1056/NEJMoa2111380 Luo, 2021, ESCORT—1st Investigators effect of Camrelizumab vs. Placebo added to chemotherapy on survival and progression-free survival in patients with advanced or metastatic esophageal squamous cell carcinoma: the ESCORT-1st randomized Clinical trial, JAMA, 326, 916, 10.1001/jama.2021.12836 Pape, 2022, Treatment patterns and survival in advanced unresectable esophageal squamous cell cancer: a population-based study, Cancer Sci., 113, 1038, 10.1111/cas.15262 Obermannová, 2022, Oesophageal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up, Ann. Oncol., 33, 992, 10.1016/j.annonc.2022.07.003 van den Ende, 2020, Priming the tumor immune microenvironment with chemo (radio) therapy: a systematic review across tumor types, Biochim. Biophys. Acta. Rev. Cancer, 1874, 10.1016/j.bbcan.2020.188386 Rha, 2023, Pembrolizumab (pembro) plus chemotherapy (chemo) as first-line therapy for advanced HER2-negative gastric or gastroesophageal junction (G/GEJ) cancer: phase III KEYNOTE-859 study, Ann. Oncol., 34, 319, 10.1016/j.annonc.2023.01.006 Zheng, 2020, Immune suppressive landscape in the human esophageal squamous cell carcinoma microenvironment, Nat. Commun., 11, 6268, 10.1038/s41467-020-20019-0